IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling

Journal of Immunology

Volumn 190, Issue 2, 2013, Pages 703-711

  Hoge, Judith ^a   Yan, Isabell ^a   Jänner, Nathalie ^b   Schumacher, Valéa ^a   Chalaris, Athena ^b   Steinmetz, Oliver M ^a   Engel, Daniel R ^c   Scheller, Jürgen ^d   Rose John, Stefan ^b   Mittruc̈ker, Hans Willi ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOREGULATION; INFECTION CONTROL; INFECTION RESISTANCE; INNATE IMMUNITY; LISTERIOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CYTOKINE RECEPTOR GP130; GENE EXPRESSION; IMMUNITY, INNATE; INTERLEUKIN-6; LISTERIA MONOCYTOGENES; LISTERIOSIS; MICE; MICE, KNOCKOUT; MONOCYTES; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84872182482     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201044     Document Type: Article

References (57)

1. Scheller, J., A. Chalaris, D. Schmidt-Arras, and S. Rose-John. 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 1813: 878-888.
2. Chalaris, A., C. Garbers, B. Rabe, S. Rose-John, and J. Scheller. 2011. The soluble interleukin 6 receptor: generation and role in inflammation and cancer. Eur. J. Cell Biol. 90: 484-494.
3. Kishimoto, T., S. Akira, M. Narazaki, and T. Taga. 1995. Interleukin-6 family of cytokines and gp130. Blood 86: 1243-1254.
4. H17 and regulatory T cells. Nature 441: 235-238.
5. Weaver, C. T., R. D. Hatton, P. R. Mangan, and L. E. Harrington. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25: 821-852.
6. Kopf, M., H. Baumann, G. Freer, M. Freudenberg, M. Lamers, T. Kishimoto, R. Zinkernagel, H. Bluethmann, and G. Köhler. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342.
7. Dube, P. H., S. A. Handley, J. Lewis, and V. L. Miller. 2004. Protective role of interleukin-6 during Yersinia enterocolitica infection is mediated through the modulation of inflammatory cytokines. Infect. Immun. 72: 3561-3570.
8. Dann, S. M., M. E. Spehlmann, D. C. Hammond, M. Iimura, K. Hase, L. J. Choi, E. Hanson, and L. Eckmann. 2008. IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. J. Immunol. 180: 6816-6826.
9. Bienz, M., W. J. Dai, M. Welle, B. Gottstein, and N. Müller. 2003. Interleukin-6-deficient mice are highly susceptible to Giardia lamblia infection but exhibit normal intestinal immunoglobulin A responses against the parasite. Infect. Immun. 71: 1569-1573.
10. LeBlanc, R. A., L. Pesnicak, E. S. Cabral, M. Godleski, and S. E. Straus. 1999. Lack of interleukin-6 (IL-6) enhances susceptibility to infection but does not alter latency or reactivation of herpes simplex virus type 1 in IL-6 knockout mice. J. Virol. 73: 8145-8151.
11. Williams, D. M., B. G. Grubbs, T. Darville, K. Kelly, and R. G. Rank. 1998. A role for interleukin-6 in host defense against murine Chlamydia trachomatis infection. Infect. Immun. 66: 4564-4567.
12. Ladel, C. H., C. Blum, A. Dreher, K. Reifenberg, M. Kopf, and S. H. Kaufmann. 1997. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect. Immun. 65: 4843-4849.
13. Suzuki, Y., S. Rani, O. Liesenfeld, T. Kojima, S. Lim, T. A. Nguyen, S. A. Dalrymple, R. Murray, and J. S. Remington. 1997. Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect. Immun. 65: 2339-2345.
14. Dalrymple, S. A., R. Slattery, D. M. Aud, M. Krishna, L. A. Lucian, and R. Murray. 1996. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect. Immun. 64: 3231-3235.
15. + T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J. Exp. Med. 183: 1345-1355.
16. Nowell, M. A., P. J. Richards, S. Horiuchi, N. Yamamoto, S. Rose-John, N. Topley, A. S. Williams, and S. A. Jones. 2003. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. 171: 3202-3209.
17. Ohshima, S., Y. Saeki, T. Mima, M. Sasai, K. Nishioka, S. Nomura, M. Kopf, Y. Katada, T. Tanaka, M. Suemura, and T. Kishimoto. 1998. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl. Acad. Sci. USA 95: 8222-8226.
18. Okuda, Y., S. Sakoda, C. C. Bernard, H. Fujimura, Y. Saeki, T. Kishimoto, and T. Yanagihara. 1998. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 10: 703-708.
19. Nishimoto, N., and T. Kishimoto. 2006. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2: 619-626.
20. Rose-John, S., J. Scheller, G. Elson, and S. A. Jones. 2006. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J. Leukoc. Biol. 80: 227-236.
21. Honda, M., S. Yamamoto, M. Cheng, K. Yasukawa, H. Suzuki, T. Saito, Y. Osugi, T. Tokunaga, and T. Kishimoto. 1992. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J. Immunol. 148: 2175-2180.
22. Rose-John, S., G. H. Waetzig, J. Scheller, J. Grötzinger, and D. Seegert. 2007. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin. Ther. Targets 11: 613-624.
23. Rose-John, S., and P. C. Heinrich. 1994. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 300: 281-290.
24. Rabe, B., A. Chalaris, U. May, G. H. Waetzig, D. Seegert, A. S. Williams, S. A. Jones, S. Rose-John, and J. Scheller. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111: 1021-1028.
25. Jostock, T., J. Müllberg, S. Ozbek, R. Atreya, G. Blinn, N. Voltz, M. Fischer, M. F. Neurath, and S. Rose-John. 2001. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268: 160-167.
26. Barkhausen, T., T. Tschernig, P. Rosenstiel, M. van Griensven, R. P. Vonberg, M. Dorsch, A. Mueller-Heine, A. Chalaris, J. Scheller, S. Rose-John, et al. 2011. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit. Care Med. 39: 1407-1413.
27. Sodenkamp, J., G. H. Waetzig, J. Scheller, D. Seegert, J. Grötzinger, S. Rose-John, S. Ehlers, and C. Hölscher. 2012. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology 217: 996-1004.
28. Nowell, M. A., A. S. Williams, S. A. Carty, J. Scheller, A. J. Hayes, G. W. Jones, P. J. Richards, S. Slinn, M. Ernst, B. J. Jenkins, et al. 2009. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J. Immunol. 182: 613-622.
29. Atreya, R., J. Mudter, S. Finotto, J. Müllberg, T. Jostock, S. Wirtz, M. Schütz, B. Bartsch, M. Holtmann, C. Becker, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6: 583-588.
30. Melton, L., and A. Coombs. 2008. Actemra poised to launch IL-6 inhibitors. Nat. Biotechnol. 26: 957-959.
31. Gellin, B. G., and C. V. Broome. 1989. Listeriosis. JAMA 261: 1313-1320.
32. Pamer, E. G. 2004. Immune responses to Listeria monocytogenes. Nat. Rev. Immunol. 4: 812-823.
33. Shi, C., and E. G. Pamer. 2011. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11: 762-774.
34. Dalrymple, S. A., L. A. Lucian, R. Slattery, T. McNeil, D. M. Aud, S. Fuchino, F. Lee, and R. Murray. 1995. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect. Immun. 63: 2262-2268.
35. Betz, U. A., W. Bloch, M. van den Broek, K. Yoshida, T. Taga, T. Kishimoto, K. Addicks, K. Rajewsky, and W. Müller. 1998. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J. Exp. Med. 188: 1955-1965.
36. Liu, Z., R. J. Simpson, and C. Cheers. 1995. Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection. Immunology 85: 562-567.
37. Liu, Z., R. J. Simpson, and C. Cheers. 1994. Role of IL-6 in activation of T cells for acquired cellular resistance to Listeria monocytogenes. J. Immunol. 152: 5375-5380.
38. Miura, T., S. Nishikawa, S. Sasaki, K. Yamada, S. Hasegawa, D. Mizuki, M. Mizuki, I. Hatayama, K. Sekikawa, Y. Tagawa, et al. 2000. Roles of endogenous cytokines in liver apoptosis of mice in lethal Listeria monocytogenes infection. FEMS Immunol. Med. Microbiol. 28: 335-341.
39. Nakane, A., A. Numata, and T. Minagawa. 1992. Endogenous tumor necrosis factor, interleukin-6, and g interferon levels during Listeria monocytogenes infection in mice. Infect. Immun. 60: 523-528.
40. Abram, M., D. Vu ković, B. Wraber, and M. Dorić. 2000. Plasma cytokine response in mice with bacterial infection. Mediators Inflamm. 9: 229-234.
41. Ehlers, S., M. E. Mielke, T. Blankenstein, and H. Hahn. 1992. Kinetic analysis of cytokine gene expression in the livers of naive and immune mice infected with Listeria monocytogenes: the immediate early phase in innate resistance and acquired immunity. J. Immunol. 149: 3016-3022.
42. Tenhumberg, S., G. H. Waetzig, A. Chalaris, B. Rabe, D. Seegert, J. Scheller, S. Rose-John, and J. Grötzinger. 2008. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J. Biol. Chem. 283: 27200-27207.
43. Kuziel, W. A., S. J. Morgan, T. C. Dawson, S. Griffin, O. Smithies, K. Ley, and N. Maeda. 1997. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. USA 94: 12053-12058.
44. Kim, K. J., J. Abrams, M. Alphonso, M. Pearce, G. J. Thorbecke, and M. A. Palladino. 1990. Role of endogenously produced interleukin-6 as a second signal in murine thymocyte proliferation induced by multiple cytokines: regulatory effects of transforming growth factor-beta. Cell. Immunol, 131: 261-271.
45. Panzer, U., O. M. Steinmetz, H. J. Paust, C. Meyer-Schwesinger, A. Peters, J.-E. Turner, G. Zahner, F. Heymann, C. Kurts, H. Hopfer, et al. 2007. Chemokine receptor CXCR3 mediates T cell recruitment and tissue injury in nephrotoxic nephritis in mice. J. Am. Soc. Nephrol. 18: 2071-2084.
46. + neutrophils are dispensable for defense against systemic Listeria monocytogenes infection. J. Immunol. 187: 5293-5298.
47. Carr, K. D., A. N. Sieve, M. Indramohan, T. J. Break, S. Lee, and R. E. Berg. 2011. Specific depletion reveals a novel role for neutrophil-mediated protection in the liver during Listeria monocytogenes infection. Eur. J. Immunol. 41: 2666-2676.
48. Serbina, N. V., and E. G. Pamer. 2006. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 7: 311-317.
49. Klouche, M., S. Bhakdi, M. Hemmes, and S. Rose-John. 1999. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J. Immunol. 163: 4583-4589.
50. Hotson, A. N., J. W. Hardy, M. B. Hale, C. H. Contag, and G. P. Nolan. 2009. The T cell STAT signaling network is reprogrammed within hours of bacteremia via secondary signals. J. Immunol. 182: 7558-7568.
51. Garbers, C., W. Thaiss, G. W. Jones, G. H. Waetzig, I. Lorenzen, F. Guilhot, R. Lissilaa, W. G. Ferlin, J. Grötzinger, S. A. Jones, et al. 2011. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J. Biol. Chem. 286: 42959-42970.
52. + T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J. Immunol. 184: 2130-2139.
53. Briso, E. M., O. Dienz, and M. Rincon. 2008. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J. Immunol. 180: 7102-7106.
54. McFarland-Mancini, M. M., H. M. Funk, A. M. Paluch, M. Zhou, P. V. Giridhar, C. A. Mercer, S. C. Kozma, and A. F. Drew. 2010. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J. Immunol. 184: 7219-7228.
55. Chalaris, A., B. Rabe, K. Paliga, H. Lange, T. Laskay, C. A. Fielding, S. A. Jones, S. Rose-John, and J. Scheller. 2007. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 110: 1748-1755.
56. Shi, C., T. Jia, S. Mendez-Ferrer, T. M. Hohl, N. V. Serbina, L. Lipuma, I. Leiner, M. O. Li, P. S. Frenette, and E. G. Pamer. 2011. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating Toll-like receptor ligands. Immunity 34: 590-601.
57. Shi, C., P. Velázquez, T. M. Hohl, I. Leiner, M. L. Dustin, and E. G. Pamer. 2010. Monocyte trafficking to hepatic sites of bacterial infection is chemokine independent and directed by focal intercellular adhesion molecule-1 expression. J. Immunol. 184: 6266-6274.